Trial Profile
Pharmacokinetics of Co-formulated Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Disoproxil Fumarate following Switch from Efavirenz/Emtricitabine/Tenofovir Disoproxil Fumarate in Healthy Subjects.
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 24 Feb 2016
Price :
$35
*
At a glance
- Drugs Elvitegravir/emtricitabine/tenofovir disoproxil fumarate/cobicistat (Primary)
- Indications HIV-1 infections
- Focus Pharmacokinetics
- 24 Feb 2016 New trial record
- 16 Feb 2016 Results published in the JAIDS